A systematic review of adherence to oral antineoplastic therapies

Oncologist

Volumn 21, Issue 3, 2016, Pages 354-376

  Greer, Joseph A ^a   Amoyal, Nicole ^a   Nisotel, Lauren ^a   Fishbein, Joel N ^a   Macdonald, James ^a   Stagl, Jamie ^a   Lennes, Inga ^a   Temel, Jennifer S ^a   Safren, Steven A ^b   Pirl, William F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Antineoplastic agents; Chemotherapy; Endocrine therapy; Medication adherence; Oral drug administration; Patient adherence

Indexed keywords

ANTINEOPLASTIC AGENT;

HUMAN; MEDICATION COMPLIANCE; NEOPLASMS; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENTS; HUMANS; MEDICATION ADHERENCE; NEOPLASMS;

EID: 84960492119     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0405     Document Type: Article

References (91)

1. O’Neill VJ, Twelves CJ. Oral cancer treatment: Developments in chemotherapy and beyond. Br J Cancer 2002;87:933–937.
2. Findlay M, von Minckwitz G,Wardley A. Effective oral chemotherapy for breast cancer: pillars of strength. Ann Oncol 2008;19:212–222.
3. Borner M, Scheithauer W, Twelves C et al. Answering patients’ needs: Oral alternatives to intravenous therapy. The Oncologist 2001;6(suppl 4):12–16.
4. Weingart SN, Brown E, Bach PB et al. NCCN Task ForceReport: Oralchemotherapy. J NatlComprCanc Netw 2008;6(suppl 3):S1–S14.
5. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44–47.
6. World Health Organization. Adherence to long-term therapies: Evidence for action. Geneva, Switzerland: World Health Organization, 2003.
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–497.
8. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009;59:56–66.
9. Partridge AH, Avorn J, Wang PS et al. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652–661.
10. Mathes T, Pieper D, Antoine S L et al. Adherence influencing factors in patients taking oral anticancer agents: A systematic review. Cancer Epidemiol 2014; 38:214–226.
11. Murphy CC, Bartholomew LK, Carpentier MY et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res Treat 2012; 134:459–478.
12. Al-Barrak J, Cheung WY. Adherence to imatinib therapyingastrointestinal stromaltumors and chronic myeloid leukemia. Support Care Cancer 2013;21: 2351–2357.
13. Given BA, Spoelstra SL, Grant M. The challenges of oral agents as antineoplastic treatments. Semin Oncol Nurs 2011;27:93–103.
14. Makubate B, Donnan PT, Dewar JA et al. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 2013;108:1515–1524.
15. Wu EQ, Johnson S, Beaulieu N et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010;26:61–69.
16. Ganesan P, Sagar TG, Dubashi B et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011;86:471–474.
17. Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011;126:529–537.
18. McCowan C, Wang S, Thompson AM et al. The value of high adherencetotamoxifeninwomenwith breast cancer: a community-based cohort study. Br J Cancer 2013;109:1172–1180.
19. Weingart SN, Flug J, Brouillard D et al. Oral chemotherapy safety practices atUScancer centres: questionnaire survey. BMJ 2007;334:407.
20. Weingart SN, Li JW, Zhu J et al. US Cancer Center Implementation of ASCO/Oncology Nursing Society Chemotherapy Administration Safety Standards. J Oncol Pract 2012;8:7–12.
21. Greer JA, Lennes IT, Gallagher ER et al. Documentation of oral versus intravenous chemotherapy plans in patients with metastatic nonsmall- cell lung cancer. J Oncol Pract 2014;10: e103–e106.
22. Neuss MN, Polovich M, McNiff K et al. 2013 updated American Society of Clinical Oncology/ Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract 2013;9(suppl): 5s–13s.
23. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. Ann Intern Med 2009;151:264–269, W64.
24. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. 2011. Available at http://www.cochranehandbook. org. Accessed March 24, 2015.
25. Radulescu M, Diepgen TL, Weisshaar E et al. What makes a good prevalence survey. Evidence Based Dermatol 2009;2:61–67.
26. Dilworth S, Higgins I, Parker V et al. Patient and health professional’s perceived barriers to the delivery of psychosocial care to adults with cancer: A systematic review. Psychooncology 2014;23:601–612.
27. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Ann Intern Med 2007;147:573–577.
28. Oberguggenberger AS, Sztankay M, Beer B et al. Adherence evaluation of endocrine treatment in breast cancer: methodological aspects. BMC Cancer 2012;12:474.
29. Grundmark B, Garmo H, Zethelius B et al. Antiandrogen prescribing patterns, patient treatment adherence and influencing factors; results from the nationwide PCBaSe Sweden. Eur J Clin Pharmacol 2012;68:1619–1630.
30. Xu S, Yang YR, Tao W et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat 2012;136:495–502.
31. Grunfeld EA, Hunter MS, Sikka P et al. Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005;59: 97–102.
32. Brier MJ, Chambless D, Gross R et al. Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors. Eur J Cancer 2015;51: 1890–1896
33. Weaver KE, Camacho F, Hwang W et al. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-incomewomen. AmJ Clin Oncol 2013;36: 181–187.
34. Ziller V, Kalder M, Albert US et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009;20: 431–436.
35. Partridge AH, Wang PS, Winer EP et al. Nonadherence to adjuvant tamoxifen therapy inwomen with primary breast cancer. J Clin Oncol 2003;21: 602–606.
36. Sedjo RL, DevineS.Predictors ofnon-adherence to aromatase inhibitorsamong commercially insured women with breast cancer. Breast Cancer Res Treat 2011;125:191–200.
37. Lee HS, Lee JY, Ah YM et al. Low adherence to upfront and extended adjuvant letrozole therapy among early breast cancer patients in a clinical practice setting. Oncology 2014;86: 340–349
38. Wu EQ, Guerin A, Yu AP et al. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in 623.
39. Guérin A, Chen L, Wu EQ et al. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin 2012; 28:1155–1162.
40. Trivedi D, Landsman-Blumberg P, Darkow T et al. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. J Manag Care Spec Pharm 2014;20:1006–1015.
41. Krolop L, Ko YD, Schwindt PF et al. Adherence management for patients with cancer taking capecitabine:Aprospective two-armcohort study. BMJ Open 2013;3:e003139.
42. Noens L, van Lierde MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronicmyeloid leukemia: The ADAGIO study. Blood 2009;113:5401–5411.
43. Hadji P, Blettner M, Harbeck N et al. The Patient’s Anastrozole Compliance to Therapy (PACT) Program: A randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausalwomen with early breast cancer. Ann Oncol 2013;24: 1505–1512.
44. Neven P, Markopoulos C, Tanner M et al. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: First-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study. Breast 2014;23: 393–399.
45. Sommers RM, Miller K, Berry DL. Feasibility pilot on medication adherence and knowledge in ambulatory patients with gastrointestinal cancer. Oncol Nurs Forum 2012;39:E373–E379.
46. Ziller V, Kyvernitakis I, Knöll D et al. Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment–the COMPAS study. BMC Cancer 2013;13:407.
47. Gebbia V, Bellavia M, Banna GL et al. Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. Clin Lung Cancer 2013; 14:390–398.
48. Khandelwal N, Duncan I, Ahmed T et al. Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions. J Natl Compr Canc Netw 2012;10: 618–625.
49. Simons S, Ringsdorf S, Braun M et al. Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 2011;19: 1009–1018.
50. Moon JH, Sohn SK, Kim SN et al. Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients. Med Oncol 2012;29:1179–1185.
51. Schneider SM, Adams DB, Gosselin T. A tailored nurse coaching intervention for oral chemotherapy adherence. J Adv Pract Oncol 2014;5:163–172.
52. Macintosh PW, Pond GR, Pond BJ et al. A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl) 2007;16: 380–386.
53. Spoelstra SL, Given BA, Given CW et al. An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: An exploratory study. Cancer Nurs 2013;36:18–28.
54. Bender CM, Gentry AL, Brufsky AM et al. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 2014;41:274–285.
55. Ma AM, Barone J, Wallis AE et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg 2008;196:500–504.
56. Maurice A, Howell A, Evans DG et al. Predicting compliance in a breast cancer prevention trial. Breast J 2006;12:446–450.
57. Bhattacharya D, Easthall C, Willoughby KA et al. Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract 2012;18:333–342.
58. Figueiredo Junior AG, Forones NM. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer. Arq Gastroenterol 2014;51:186–191.
59. Jönsson S, Olsson B, Söderberg J et al Good adherence to imatinib therapy among patients with chronic myeloid leukemia–a single-center observational study. Ann Hematol 2012;91: 679–685.
60. Mazzeo F, Duck L, Joosens E et al. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: The ADAGIO study. Anticancer Res 2011;31:1407–1409.
61. Ruddy KJ, Pitcher BN, Archer LE et al. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol 2012;23:3075–3081.
62. Winterhalder R, Hoesli P, Delmore G et al. Selfreported compliance with capecitabine: Findings from a prospective cohort analysis. Oncology 2011; 80:29–33.
63. Santoleri F, Sorice P, Lasala R et al. Patient adherence and persistence with imatinib, nilotinib, dasatinib in clinical practice. PLoS One 2013;8: e56813.
64. Thivat E, Van Praagh I, Belliere A et al. Adherence with oral oncologic treatment in cancer patients: Interest of an adherence score of all dosing errors. Oncology 2013;84:67–74.
65. Harbeck N, Blettner M, Hadji P et al. Patient’s Anastrozole Compliance to Therapy (PACT) Program: baseline data and patient characteristics from a population-based, randomized study evaluating compliance to aromatase inhibitor therapy in postmenopausal women with hormonesensitive early breast cancer. Breast Care (Basel) 2013;8:110–120.
66. Simon R, Latreille J, Matte C et al. Adherence to adjuvant endocrine therapy in estrogen receptorpositive breast cancer patients with regular followup. Can J Surg 2014;57:26–32.
67. Mathes T, Antoine SL, Pieper D et al. Adherence enhancing interventions for oral anticancer agents: A systematic review. Cancer Treat Rev 2014;40: 102–108.
68. Banning M. Adherence to adjuvant therapy in post-menopausal breast cancer patients: A review. Eur J Cancer Care (Engl) 2012;21: 10–19.
69. Bassan F, Peter F, Houbre B et al. Adherence to oral antineoplastic agents by cancer patients: definition and literature review. Eur J Cancer Care (Engl) 2014;23:22–35.
70. Greer JA, Helmuth PJ, Gonzalez JS et al. Nonadherence to treatment. In: Fogel B, Greenberg D, eds. Psychiatric Care of the Medical Patient. 3rd ed.NewYork: Oxford University Press, 2015:253–265.
71. Safren SA, Gonzalez JS, Soroudi N. Coping With Chronic Illness: A Cognitive-Behavioral Therapy Approach for Adherence and Depression. New York: Oxford University Press, 2007.
72. Brito C, Portela MC, de Vasconcellos MT. Adherence to hormone therapy among women with breast cancer. BMC Cancer 2014;14:397.
73. Danilak M, Chambers CR. Adherence to adjuvant endocrine therapy in women with breast cancer. J Oncol Pharm Pract 2013;19: 105–110.
74. Font R, Espinas JA, Gil-Gil M et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: A retrospective cohort study in Catalonia, Spain. Br J Cancer 2012;107: 1249–1256.
75. Hershman DL, Kushi LH, Shao T et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120–4128.
76. Hershman DL, Tsui J, Meyer J et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst 2014; 106:dju319.
77. Hsieh KP, Chen LC, Cheung KL et al. Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women–an Asian population-based study. PLoS One 2014;9: e87027.
78. Hsieh KP, Chen LC, Cheung KL et al. Risks of nonadherence to hormone therapy in Asian women with breast cancer. Kaohsiung J Med Sci 2015;31: 328–334.
79. Klepin HD, Geiger AM, Bandos H et al. Cognitive factors associated with adherence to oral antiestrogen therapy: Results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study. Cancer Prev Res (Phila) 2014;7: 161–168.
80. McCowan C, Shearer J, Donnan PT et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008;99:1763–1768.
81. Neugut AI, Subar M, Wilde ET et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011;29:2534–2542.
82. Neuner JM, Kamaraju S, Charlson JA et al. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J Natl Cancer Inst 2015;107:djv130.
83. Partridge AH, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556–562.
84. Stanton AL, Petrie KJ, Partridge AH. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. Breast Cancer Res Treat 2014; 145:525–534.
85. Trabulsi N, Riedel K, Winslade N et al. Adherence to anti-estrogen therapy in seniors with breast cancer: How well are we doing? Breast J 2014;20: 632–638.
86. Wigertz A, Ahlgren J, Holmqvist M et al. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: A populationbased study. Breast Cancer Res Treat 2012;133: 367–373.
87. Darkow T, Henk HJ, Thomas SK et al. Treatment interruptions and non-adherence with imatinib and associatedhealthcare costs:Aretrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007;25: 481–496.
88. Efficace F, Baccarani M, Rosti G et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study. Br J Cancer 2012;107:904–909.
89. Mallick R, Cai J, Wogen J. Predictors of nonadherence to systemic oral therapy for advanced hepatocellular carcinoma. Curr Med Res Opin 2013;29:1701–1708.
90. Partridge AH, Archer L, Kornblith AB et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: Adherence companion study 60104. J Clin Oncol 2010;28:2418–2422.
91. Jacob Arriola KR, Mason TA, Bannon KA et al. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 2014;95:98–103.